The rise of ADHD as a multimillion-pound industry for private equity has sparked debates about overdiagnosis and the impact on NHS budgets. Private equity firms are profiting from investing in ADHD clinics, which provide assessment and treatment for NHS patients. The NHS has become reliant on private services for ADHD and autism diagnoses, leading to a surge in spending and long waiting lists. More than half a million people in England are on waiting lists for ADHD assessments, and the NHS is picking up the bill for private assessments under the Right to Choose initiative. This has led to a proliferation of private providers, attracting private equity investors seeking quick profits. Analysis reveals that three private-equity-backed providers generated £31.5 million in profits last year. The NHS spent £128 million on private ADHD companies in the last year, up from £36 million two years ago. Local NHS bodies have imposed caps on assessments to control spending, but charities argue this is devastating for ADHD patients. Major providers like ADHD360 offer assessment and treatment packages, with turnover and profits nearly doubling in a year. Psychiatry UK, owned by a London-based private equity firm, posted £53 million in revenue. The Centre for Health and the Public Interest's David Rowland highlights the impact of the Right to Choose scheme, where private clinics advertise on social media, and the NHS pays for assessments. ADHD clinics are seen as low-risk, high-profit opportunities for private equity. Rowland calls for profit caps on private companies delivering NHS care, citing the leakage of funds from the system. The spiraling cost of ADHD diagnosis adds to financial pressures on integrated care boards, affecting their ability to fund other basic healthcare. Some NHS ICBs have stopped accepting new referrals due to financial strain. Mark Pattison, founder of Care ADHD, argues that NHS caps impact private providers, leading to longer waits and potential emergency department visits. He suggests that private clinics often provide more cost-effective services due to better technology utilization. Rebecca Gray, mental health director, emphasizes the need for NHS leaders to prioritize those with the highest need for ADHD assessments due to financial constraints. The NHS believes ADHD is significantly underdiagnosed, with 2.5 million people potentially affected. David Hare, chief executive at the Independent Healthcare Provider Network, highlights the role of independent providers in boosting ADHD care capacity, delivering over half of NHS-funded assessments. The debate centers on balancing access to care and managing financial pressures, with questions about the impact of private equity on healthcare.
